Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gen-Probe HPV assay trial

This article was originally published in The Gray Sheet

Executive Summary

San Diego diagnostics firm Gen-Probe begins a 7,000-patient U.S. pivotal trial in late March of its Aptima molecular assay to detect human papillomavirus (HPV). The amplified nucleic acid test detects 14 high-risk HPV types associated with cervical cancer. One arm of the multi-center clinical study will enroll women whose Pap results are classified as atypical squamous cells of undetermined significance (meaning they are neither normal nor clearly indicative of progression to cervical cancer), and the other arm will enroll women over age 30 with normal Pap results. Qiagen/Digene (Hybrid Capture 2) offers the only FDA-approved molecular assay for HPV, but a number of competitors are seeking market entry (1"The Gray Sheet" Jan. 21, 2008, p. 22)

You may also be interested in...

Gen-Probe HPV test

San Diego firm launches its Aptima molecular assay for human papillomavirus (HPV) in Europe May 28 upon gaining a CE mark. The assay, which detects 14 high-risk HPV types associated with cervical cancer, runs on Gen-Probe's Tigris and DTS instrument platforms. The firm began a 7,000-patient pivotal trial for U.S. approval of Aptima in March (1"The Gray Sheet" April 7, 2008, In Brief). Qiagen/Digene's Hybrid Capture 2 is the only FDA-approved molecular test for HPV

Qiagen Monopoly In HPV Test Market Won’t Last, Judge Says

A U.S. district court turned down Third Wave Technologies' claims that Qiagen engages in anti-competitive behavior in the cervical cancer screening space, but the ruling suggests the direction of the market will be in Third Wave's favor

Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts